Brint Family Translational Research Award

This program funds research and development efforts that are creating novel, clinically relevant treatments and cures for inherited retinal disease and dry age-related macular degeneration. 
 

Priority areas are, but not limited to: 

(1) Novel Medical Therapies – approaches that use chemistry, biology, and bioengineering to formulate new therapies (e.g., small molecules, biologics) that mitigate inherited retinal degenerations and dry age-related macular degenerations.

(2) Genetic Technologies – the manipulation and modification of human gene expression to alter the biological properties of living cells/tissues with the goal of providing retinal therapeutic solutions.

(3) Regenerative Medicine – the development, regeneration, and employment of human cells, tissues, and cellular/tissue-based products for the restoration of retinal function and vision.

Funding up to $1M USD available over three years.